In addition to our regenerative medicine programs, we are focused on creating a new class of compounds that target a key receptor in the brain the 5HT2c receptor. This receptor system has been extensively validated both pre-clinically and clinically as being relevant for treating neurological conditions that involve then 5HT2 serotonin receptor system. Potent and selective compounds that act at this receptor have shown clinical potential for treating obesity and other conditions, such as schizophrenia. We have developed a novel and proprietary portfolio of compounds that exhibit best in class characteristics due to their outstanding potency and selectivity profiles, that we believe have the potential to be developed as safer and more effective medicines for these and potentially other conditions where this receptor system is clinically relevant.